Free Trial

STERIS (STE) Competitors

$222.88
-0.34 (-0.15%)
(As of 05/31/2024 ET)

STE vs. BDX, EW, DXCM, IDXX, RMD, BAX, HOLX, PODD, TFX, and GMED

Should you be buying STERIS stock or one of its competitors? The main competitors of STERIS include Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Baxter International (BAX), Hologic (HOLX), Insulet (PODD), Teleflex (TFX), and Globus Medical (GMED). These companies are all part of the "health care equipment" industry.

STERIS vs.

STERIS (NYSE:STE) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, community ranking, dividends, risk and profitability.

STERIS has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.

Becton, Dickinson and Company received 266 more outperform votes than STERIS when rated by MarketBeat users. Likewise, 62.33% of users gave Becton, Dickinson and Company an outperform vote while only 58.41% of users gave STERIS an outperform vote.

CompanyUnderperformOutperform
STERISOutperform Votes
323
58.41%
Underperform Votes
230
41.59%
Becton, Dickinson and CompanyOutperform Votes
589
62.33%
Underperform Votes
356
37.67%

STERIS has a net margin of 6.95% compared to Becton, Dickinson and Company's net margin of 6.76%. Becton, Dickinson and Company's return on equity of 13.90% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
STERIS6.95% 13.73% 7.73%
Becton, Dickinson and Company 6.76%13.90%6.73%

Becton, Dickinson and Company has higher revenue and earnings than STERIS. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STERIS$5.14B4.29$378.24M$3.8258.35
Becton, Dickinson and Company$19.37B3.46$1.48B$4.5451.11

In the previous week, Becton, Dickinson and Company had 11 more articles in the media than STERIS. MarketBeat recorded 22 mentions for Becton, Dickinson and Company and 11 mentions for STERIS. Becton, Dickinson and Company's average media sentiment score of 0.45 beat STERIS's score of 0.43 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
STERIS
4 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Becton, Dickinson and Company
9 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

94.7% of STERIS shares are held by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are held by institutional investors. 1.0% of STERIS shares are held by company insiders. Comparatively, 0.3% of Becton, Dickinson and Company shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

STERIS pays an annual dividend of $2.08 per share and has a dividend yield of 0.9%. Becton, Dickinson and Company pays an annual dividend of $3.80 per share and has a dividend yield of 1.6%. STERIS pays out 54.5% of its earnings in the form of a dividend. Becton, Dickinson and Company pays out 83.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

STERIS presently has a consensus target price of $241.60, suggesting a potential upside of 8.40%. Becton, Dickinson and Company has a consensus target price of $280.17, suggesting a potential upside of 20.74%. Given Becton, Dickinson and Company's stronger consensus rating and higher probable upside, analysts clearly believe Becton, Dickinson and Company is more favorable than STERIS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STERIS
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Becton, Dickinson and Company
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

Summary

Becton, Dickinson and Company beats STERIS on 12 of the 20 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STE vs. The Competition

MetricSTERISSurgical appliances & supplies IndustryMedical SectorNYSE Exchange
Market Cap$22.02B$8.99B$5.05B$17.88B
Dividend Yield0.93%1.29%2.83%3.57%
P/E Ratio58.3518.61168.6125.48
Price / Sales4.2951.632,349.8510.30
Price / Cash22.6821.8234.2918.87
Price / Book3.494.275.495.91
Net Income$378.24M$182.64M$105.49M$976.46M
7 Day Performance-2.74%-1.47%1.08%0.61%
1 Month Performance8.96%0.07%3.22%4.90%
1 Year Performance11.46%7.47%4.95%25.27%

STERIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BDX
Becton, Dickinson and Company
4.9013 of 5 stars
$226.78
+0.8%
$280.17
+23.5%
-4.8%$65.54B$19.37B49.9573,000Analyst Forecast
Short Interest ↓
EW
Edwards Lifesciences
4.6607 of 5 stars
$87.89
+1.0%
$95.06
+8.2%
+7.9%$52.96B$6.00B37.8819,800Analyst Forecast
Insider Selling
Short Interest ↓
DXCM
DexCom
4.9586 of 5 stars
$118.40
-7.2%
$141.67
+19.7%
+4.3%$47.09B$3.62B76.399,600Analyst Forecast
Short Interest ↓
High Trading Volume
IDXX
IDEXX Laboratories
4.3173 of 5 stars
$499.77
+0.3%
$580.38
+16.1%
+7.2%$41.28B$3.66B48.3811,000Positive News
RMD
ResMed
4.4948 of 5 stars
$209.35
+1.6%
$202.80
-3.1%
-0.3%$30.76B$4.22B32.1610,140Analyst Revision
BAX
Baxter International
4.9368 of 5 stars
$33.44
+0.8%
$44.42
+32.8%
-17.1%$17.04B$14.81B6.4360,000Analyst Forecast
Short Interest ↓
HOLX
Hologic
4.7873 of 5 stars
$72.58
+0.3%
$85.60
+17.9%
-7.7%$16.94B$4.03B37.036,990
PODD
Insulet
4.9053 of 5 stars
$175.95
+2.1%
$239.18
+35.9%
-35.5%$12.32B$1.70B53.323,000Analyst Forecast
Insider Selling
Short Interest ↑
Positive News
TFX
Teleflex
4.399 of 5 stars
$206.64
+2.0%
$257.29
+24.5%
-11.0%$9.73B$2.97B33.1714,500Short Interest ↑
High Trading Volume
GMED
Globus Medical
4.7193 of 5 stars
$66.59
+2.0%
$69.40
+4.2%
+26.6%$9.01B$1.57B104.045,000Analyst Forecast
Short Interest ↓
Analyst Revision

Related Companies and Tools

This page (NYSE:STE) was last updated on 5/31/2024 by MarketBeat.com Staff

From Our Partners